Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Edgewise Therapeutics, Inc.EWTX-24.390.0010.44-17.14-31.90%-58.38%58.76$26.87$99.8029,000$32.32

Detail of Edgewise Therapeutics, Inc.

 
CEO
Dr. Kevin Koch Ph.D.
Employees
108
Industry
Biotechnology
Sector
Healthcare
Market cap
$3B

Company details

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Edgewise Therapeutics, Inc.
EWTX • XNGS • US
$32.32
+22.80 (239.50%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$1.32
Margin profit
0.00%
52 week low
$9.25
52 week high
$36.619999
50-day simple moving average
$33.02
200-day simple moving average
$26.87
Percent held by insiders
0.46%
Percent held by institutions
111.60%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
EWTX +167.11%
eps change
EWTX 0.00%